Overview

The Effectiveness and Safety in High-risk Patients Receiving First-line Atezolizumab and Bevacizumab Combined With HAIC for HCC: a Retrospective Study

Status:
COMPLETED
Trial end date:
2025-11-10
Target enrollment:
Participant gender:
Summary
This is a multicenterretrospective study to explore the effectiveness and safety of Atezo/Bev plus hepatic artery infusion chemotherapy (HAIC) among adult patients with high-risk HCC in real-world clinical practice in China. Eligible patients diagnosed with high-risk HCC initiating the study treatment of interest between 28 October 2020 and 31 June 2025 will be included in this study. Secondary data from medical records of approximately 10 sites across China will be utilized.
Phase:
NA
Details
Lead Sponsor:
Sun Yat-sen University
Treatments:
atezolizumab
Bevacizumab